Clinical Trials Logo
  1. Home
  2. Pulmonary Alveolar Proteinosis
  3. NCT01983657

Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. — PAP  

Pulmonary Alveolar Proteinosis Clinical Trial

Official title:
Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.

Clinical Trial Summary

The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP.

Clinical Trial Description

The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP. During the observation, study visits will occur at the end of each month. During the 1-year follow-up period which is lasting 6 months after the treatment, all participants will be required to check the various efficacy indicators. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01983657
Study type Interventional
Source Shanghai Pulmonary Hospital, Shanghai, China
Contact Huiping Li, Dr
Phone 86-13817389991
Email liw2013@126.com
Status Recruiting
Phase Phase 2
Start date January 2012
Completion date October 2014
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00030056 - GM-CSF in Patients With Pulmonary Alveolar Proteinosis Phase 2
Completed NCT03887169 - Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. Phase 1/Phase 2
Completed NCT02468908 - Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Phase 1
Enrolling by invitation NCT04326036 - Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection Early Phase 1
Completed NCT03007134 - Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial N/A
Completed NCT00552461 - Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis Phase 2
Completed NCT04516577 - Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis
Recruiting NCT02852928 - European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Completed NCT02081092 - Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT
Recruiting NCT03316651 - Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis Phase 2
Enrolling by invitation NCT05300360 - Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis
Recruiting NCT02461615 - A National Registry For Pulmonary Alveolar Proteinosis